Payment overview · 2025
General Payments
$868.32
53 reported records · 9 companies
Healthcare provider profile · identity verified
Tiffany Brumley, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · POCAHONTAS, AR · NPI 1962882902
Verified facts
What the public records show
CMS Open Payments records show Tiffany Brumley, APRN received $868.32 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $325.57 | 37.5% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.56 | 17.8% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $88.01 | 10.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.03 | 9.7% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.02 | 9.1% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.60 | 6.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.60 | 3.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.28 | 3.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.65 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $868.32 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $244.41 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $151.75 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $147.21 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.26 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $118.96 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $88.01 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.03 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $79.02 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.56 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.30 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 41 |
| Lisinopril | Lisinopril | 136 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 31 |
| Omeprazole | Omeprazole | 103 | 26 |
| Losartan Potassium | Losartan Potassium | 98 | 24 |
| Gabapentin | Gabapentin | 97 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 24 |
| Furosemide | Furosemide | 85 | 23 |
| Metformin Hcl | Metformin Hcl | 84 | 23 |
| Alprazolam | Alprazolam | 78 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 74 | 18 |
| Ozempic | Semaglutide | 74 | 15 |
| Prednisone | Prednisone | 74 | 67 |
| Meloxicam | Meloxicam | 69 | 24 |
| Potassium Chloride | Potassium Chloride | 69 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 18 |
| Famotidine | Famotidine | 46 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 11 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 37 |
| Tramadol Hcl | Tramadol Hcl | 38 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 11 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 17 |
| Azithromycin | Azithromycin | 32 | 27 |
| Eliquis | Apixaban | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 25 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 21 |
| Mupirocin | Mupirocin | 24 | 21 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | 13 |
| Cephalexin | Cephalexin | 22 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 14 |
| Allopurinol | Allopurinol | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Linzess | Linaclotide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $868.32 · 53 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error